AIF-regulated Oxidative Phosphorylation Supports Lung Cancer Development
Shuan Rao,Laura Mondragón,Blanka Pranjic,Toshikatsu Hanada,Gautier Stoll,Thomas Köcher,Peng Zhang,Alexander Jais,Alexander Lercher,Andreas Bergthaler,Daniel Schramek,Katharina Haigh,Valentina Sica,Marion Leduc,Nazanine Modjtahedi,Tsung-Pin Pai,Masahiro Onji,Iris Uribesalgo,Reiko Hanada,Ivona Kozieradzki,Rubina Koglgruber,Shane J. Cronin,Zhigang She,Franz Quehenberger,Helmut Popper,Lukas Kenner,Jody J. Haigh,Oliver Kepp,Malgorzata Rak,Kaican Cai,Guido Kroemer,Josef M. Penninger
DOI: https://doi.org/10.1038/s41422-019-0181-4
2019-01-01
Abstract:Cancer is a major and still increasing cause of death in humans. Most cancer cells have a fundamentally different metabolic profile from that of normal tissue. This shift away from mitochondrial ATP synthesis via oxidative phosphorylation towards a high rate of glycolysis, termed Warburg effect, has long been recognized as a paradigmatic hallmark of cancer, supporting the increased biosynthetic demands of tumor cells. Here we show that deletion of apoptosis-inducing factor (AIF) in a Kras G12D -driven mouse lung cancer model resulted in a marked survival advantage, with delayed tumor onset and decreased malignant progression. Mechanistically, Aif deletion leads to oxidative phosphorylation (OXPHOS) deficiency and a switch in cellular metabolism towards glycolysis in non-transformed pneumocytes and at early stages of tumor development. Paradoxically, although Aif -deficient cells exhibited a metabolic Warburg profile, this bioenergetic change resulted in a growth disadvantage of Kras G12D -driven as well as Kras wild-type lung cancer cells. Cell-autonomous re-expression of both wild-type and mutant AIF (displaying an intact mitochondrial, but abrogated apoptotic function) in Aif -knockout Kras G12D mice restored OXPHOS and reduced animal survival to the same level as AIF wild-type mice. In patients with non-small cell lung cancer, high AIF expression was associated with poor prognosis. These data show that AIF-regulated mitochondrial respiration and OXPHOS drive the progression of lung cancer.